ENOVIS CORP
ENOVNYSETrading Snapshot
- Day Range
- $21.75 β $22.25
- 52-Week Range
- $16.70 β $33.13
- Volume (shares)
- 91,133
- Avg Volume (shares)
- β
- Shares Outstanding
- 57.7M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $2.25B
- Last Q Revenue
- $583M
- P/E Ratio
- -1.1
- P/S Ratio
- 0.6x
- EPS (TTM)
- $-19.13
- Dividend Yield
- 0.00%
- Dilution (1yr)
- β2.7%
ENOVIS CORP
ENOVAbout ENOVIS CORP
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionalsβincluding orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainersβwho treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates
News unavailable.